Annovis Bio Inc
Research Annovis Bio Inc (ANVS) on Bullrun: market cap USD 77.54M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANVS
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 77.54M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 17.61M
- Free cash flow-USD 9.01M
Valuation Snapshot
latest market cap is USD 77.54M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 28.85M | -USD 25.62M | n/a | -1.4 | USD 19.53M | n/a | USD 16.85M |
| FY2024 | USD 0 | -USD 24.59M | -USD 21.89M | n/a | -2.31 | USD 10.55M | n/a | USD 9.31M |
| FY2023 | USD 0 | -USD 56.20M | -USD 39.97M | n/a | -6.23 | USD 5.75M | n/a | -USD 7.75M |
| FY2022 | USD 0 | -USD 25.33M | n/a | n/a | -3.1 | USD 28.38M | n/a | USD 28.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 77.54M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 94.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 71.13M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 191.91M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 109.64M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 142.41M | n/a | n/a | n/a |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Annovis Bio Inc's market cap?
Annovis Bio Inc's market capitalization is USD 77.54M.
What does Annovis Bio Inc do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc.